The US, Canada and Mexico have signed a new, finalised trade agreement to replace the old North American Free Trade Agreement.
US senators have requested information regarding the national security risks posed by the role of foreign manufacturing, specifically in China, in the US pharmaceutical products supply chain.
Sanofi is to acquire Synthorx, a biotechnology company focused on improving the lives of people suffering from cancer and autoimmune diseases, for $2.5 billion.
Treatment Action Group, a US-based organisation focused on research of diseases such as HIV/AIDS and tuberculosis, has applauded an opposition that aims to block Sanofi from patenting a new TB drug in India.
Takeda has sued Mylan for patent infringement and breach of a licencing agreement over Takeda’s Colcrys drug.
The US Senate Committee on Health, Education, Labor and Pensions has approved President Donald Trump’s nomination for Stephen Hahn to serve as the new commissioner of the Food and Drug Administration.
Astellas is set to buy US-based Audentes Therapeutics for approximately $3 billion, as the Japanese pharmaceutical company looks to boost its gene therapy expertise.
The Trump administration is considering shortening the period that big pharma companies’ biologic drugs are protected by marketing exclusivity from biosimilar competition.
Genus Lifesciences is suing pharmaceutical company Mallinckrodt for misusing trade secrets related to a cocaine hydrochloride formulation.
China has added 70 medicines to its national medical insurance catalogue, which will reduce the cost of the drugs by more than 60% on average, the National Healthcare Security Administration has said.